Form 4: Bicara Therapeutics COO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Ryan Cohlhepp, President and COO and a Director of Bicara Therapeutics Inc., sold 18,750 shares of common stock on August 10, 2026 for $27.98 per share.

Summary

  • Option exercise/conversion: acquired 18,750 Common Stock at $3.79 ($71,059) on August 10, 2026; holds 200,391 after (Direct).
  • Open-market sale: disposed of 18,750 Common Stock at $27.98 ($524,533) on August 10, 2026; holds 181,641 after (Direct).
  • Option exercise/conversion: disposed of 18,750 Stock Option (Right to Buy) on August 10, 2026; holds 51,752 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $524,533 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Ryan Cohlhepp — Director, Officer (President and COO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-10Option exercise/conversionCommon Stock18,750$4$71.1K200,391
2026-08-10Open-market saleCommon Stock18,750$28$524.5K181,641
2026-08-10Option exercise/conversionStock Option (Right to Buy)18,750——51,752

Key Dates

DateDescription
2026-08-10Option exercise/conversion (18,750 shares)
2026-08-10Open-market sale (18,750 shares)
2026-08-10Option exercise/conversion (18,750 shares)

Keywords

insider transaction, Form 4, BCAX, Bicara Therapeutics Inc., bearish, Ryan Cohlhepp

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.